Tango Therapeutics, Inc. (TNGX)

NASDAQ: TNGX · IEX Real-Time Price · USD
3.41
-0.21 (-5.80%)
Oct 3, 2022 4:00 PM EDT - Market closed
-5.80%
Market Cap 300.31M
Revenue (ttm) 24.03M
Net Income (ttm) -91.70M
Shares Out 88.07M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,004
Open 3.70
Previous Close 3.62
Day's Range 3.30 - 3.79
52-Week Range 3.18 - 14.96
Beta 0.77
Analysts Buy
Price Target 15.71 (+360.7%)
Earnings Date Nov 7, 2022

About TNGX

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilea... [Read more...]

Industry Biotechnology
Founded 2014
Employees 103
Stock Exchange NASDAQ
Ticker Symbol TNGX
Full Company Profile

Financial Performance

In 2021, TNGX's revenue was $37.04 million, an increase of 383.83% compared to the previous year's $7.66 million. Losses were -$58.24 million, 12.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for TNGX stock is "Buy." The 12-month stock price forecast is 15.71, which is an increase of 360.70% from the latest price.

Price Target
$15.71
(360.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medi...

3 weeks ago - GlobeNewsWire

Can Tango Therapeutics, Inc. (TNGX) Climb 219% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 219.4% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is question...

1 month ago - Zacks Investment Research

Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

– Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor –

1 month ago - GlobeNewsWire

Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medic...

3 months ago - GlobeNewsWire

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

– Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment –

4 months ago - GlobeNewsWire

Wall Street Analysts Predict a 176% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 176.2% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is question...

5 months ago - Zacks Investment Research

Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

- TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 -

6 months ago - GlobeNewsWire

Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platfor...

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medi...

6 months ago - GlobeNewsWire

Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer The...

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medi...

7 months ago - GlobeNewsWire

Tango Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medic...

8 months ago - GlobeNewsWire

Tango Therapeutics' TNG908 IND For Cancer Study Gets Green Signal By FDA

The FDA has cleared Tango Therapeutics Inc's (NASDAQ: TNGX) Investigational New Drug (IND) application for its lead program, TNG908. TNG908 is a synthetic lethal small molecule inhibitor of protein argi...

8 months ago - Benzinga

Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates

- TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022

8 months ago - GlobeNewsWire

Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

- Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 -

10 months ago - GlobeNewsWire

Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medic...

11 months ago - GlobeNewsWire

Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstract...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today annou...

1 year ago - Business Wire

Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm

Wedbush initiated coverage of Tango Therapeutics Inc (NASDAQ: TNGX) with an Outperform rating and a $12 price target.  Analyst Robert Driscoll believes Tango's unique synthetic lethality approach is dif...

1 year ago - Benzinga